Why did TMD.TO stock spike pre-market today?

The pre-market spike to **C$1.125** on 26 Jan 2026 came with **117,220** shares traded. The move appears driven by low liquidity and concentrated orders, plus speculative interest ahead of possible news on Titan Medical’s Enos program.

What is Meyka AI's grade for TMD.TO stock and what does it mean?

Meyka AI rates TMD.TO with a score out of 100: **64.61 / B — HOLD**. The grade blends benchmarks, sector and financial metrics. It signals caution and suggests waiting for clearer fundamentals before long-term buying.

What short-term trading rules apply to TMD.TO stock today?

Use small position sizes, tight stop-losses, and scale exits. Watch intraday support at **C$0.05** and resistance near **C$1.25**. Heavy volume can reverse quickly in low-float stocks like TMD.TO.

What price does Meyka AI forecast for TMD.TO stock?

Meyka AI's forecast model projects a 12-month target of **C$0.45** versus the current **C$1.125**, implying **-60.00%** downside. Forecasts are model-based and not guarantees.

CA Stocks

TMD.TO stock C$1.13 on 117,220 pre-market 26 Jan 2026: key catalysts

ByDanny Kontos January 26, 2026January 26, 2026

TMD.TO stock jumped to C$1.125 in pre-market trading on 26 Jan 2026, driven by unusual activity of 117,220 shares versus an average of 45,936. The move follows an open at C$0.05 and a previous close of C$0.05, creating a one-day swing of +2149.99% on headline data. For traders scanning high-volume movers in the TSX healthcare slice, this spike combines low float dynamics and speculative interest with underlying corporate milestones tied to Titan Medical Inc.’s Enos surgical program. We break down the drivers, valuation, risks and a short-term Meyka AI forecast for active traders.